Cargando…
Lobo-isthmectomy in the management of differentiated thyroid cancer
We have recently witnessed a rapid increase in the incidence of differentiated thyroid carcinoma (DTC), particularly low and very low-risk papillary thyroid carcinoma. Simultaneously, the number of cancer-related deaths has remained stable for more than 30 years. Such an indolent nature and long-ter...
Autores principales: | Krajewska, Jolanta, Kukulska, Aleksandra, Samborski, Konrad, Czarniecka, Agnieszka, Jarzab, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923929/ https://www.ncbi.nlm.nih.gov/pubmed/36775829 http://dx.doi.org/10.1186/s13044-022-00145-1 |
Ejemplares similares
-
Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
por: Rusinek, Dagmara, et al.
Publicado: (2017) -
Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019) -
Current status of the prognostic molecular markers in medullary thyroid carcinoma
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2020) -
Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
por: Wojtas, Bartosz, et al.
Publicado: (2017) -
Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)